Lipid Disorder Treatment Market
Global Lipid Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypercholesterolemia, Dysbetalipoproteinemia, Familial Combined Hyperlipidemia, and Others), By Product Type (Atorvastatin, Simvastatin, Pravastatin, Rosuvastatin, Lovastatin, and Other), By Distribution Channel (Hospital & Clinics, Retail Pharmacies, and Online Pharmacies), Forecast Period (2020-2026)
The lipid disorder treatment market is anticipated to grow at a CAGR of around 7.5% during the forecast period. Lipid disorders are the problems associated with the various forms of fat that are carried in the bloodstream such as high-density lipoproteins (HDL), low-density lipoproteins (LDL), and triglycerides. Factors such as genetics and lifestyle or both in combination trigger the blood lipid levels. In some cases, lipid disorders can also be caused by another disease or a medical condition called secondary lipid disorders or by steroid use.
Moreover, factor such as low-cost screening of lipid disorders is anticipated to drive the lipid disorder treatment market. In addition to this, the easy availability of treatment options at affordable cost is also expected to promote more and more people to seek the treatment. Besides, the increasing R&D activities across the globe to lower the risk of cardiovascular diseases is presenting new opportunities to the lipid disorder treatment market growth.
Segmental Outlook
The global Lipid disorder treatment market is segmented based on the indication, product type, and distribution channel. Based on the indication, the market is sub-segmented into hypercholesterolemia, dysbetalipoproteinemia, familial combined hyperlipidemia, and others. On the basis of product type, the market is sub-divided into atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, and others. Atorvastatin is expected to hold a major market share during the forecast period as it is one of the most common drugs to be prescribed all across the globe. For instance, in the US, atorvastatin was the second most prescribed drug in the US in 2017 with around 104 million prescriptions in the whole year. Further, based on the distribution channel, the market is sub-segmented into hospitals & clinics, retail pharmacies, and online pharmacies.
The familial combined hyperlipidemia segment by the indication will show a considerable growth
The familial combined hyperlipidemia segment is anticipated to grow with a significant growth rate in the lipid disorder treatment market. The growth of the segment is owing to its high prevalence which in turn is attracting more and more drug manufacturers to involve in its treatment market. Statins are the most common class of drug that is used to treat familial combined hyperlipidemia. A similar drug class is also used to treat related conditions like obesity hence, this will also contribute significantly to the growth of the segment.
Global Lipid disorder treatment market Share by familial combined hyperlipidemia, 2019 (%)
Regional Outlooks
The global lipid disorder treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a significant share in the lipid disorder treatment market during the forecast period. The high cost of drugs, high diagnosis rate, and well-developed healthcare infrastructure are some of the major factors for the significant market share of the region. Moreover, the strong presence of key industry players in the North American lipid disorder treatment market will also aid in its growth. Increasing prevalence of cardiovascular diseases, unhealthy eating habits, well-developed healthcare infrastructure are expected to augment the European market during the forecast period.
Global Lipid Disorder Treatment Market Growth, by Region 2020-2026
Asia-Pacific will augment with the fastest growth rate in the lipid disorder treatment market
Asia-Pacific is anticipated to show the fastest growth rate in the lipid disorder treatment market owing to the high prevalence of lipid disorders such as dyslipidaemia, low high-density lipoprotein cholesterol (HDL-C), high triglycerides (TG), and many more. Additionally, the further development of healthcare infrastructure and so the diagnosis rate of cardiovascular disease across the region is also aiding in the lipid disorder treatment market. Moreover, the shift from traditional diets to high-fat diets and reduced physical activity is also contributing to the rising cases of lipid disorder across the region. This in turn will fuel the growth of lipid disorder treatment market across the Asia-Pacific region.
Market Players Outlook
Lipid disorder treatment market is a fragmented market however the key players active in the market include Avanti Polar Lipids, ESPERION Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Micelle BioPharma, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Zydus Cadila, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger, & acquisition, collaborations with government, funding to the start-ups, and new product launches to stay competitive in the market.
Recent Activities
- In March 2020, Novartis AG announced the positive results from the Phase III studies evaluating the safety and efficacy of Inclisiran. It is intended for the treatment of hyperlipidemia in adults. The results presented have indicated that Inclisiran has the potential to be the first small interfering RNA (siRNA) agent which will aid patients to get their LDL-C to desired levels,
- In July 2019, Sun Pharmaceutical Industries Ltd. launched Ezallor Sprinkle (rosuvastatin) capsules in the US for the treatment of certain elevated lipid disorders. This is intended to especially serve people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Lipid disorder treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Astrazeneca Plc
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Pfizer Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Ionis Pharmaceuticals, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Merck & Co. Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Lipid Disorder Treatment Market by Indication
5.1.1. Hypercholesterolemia
5.1.2. Dysbetalipoproteinemia
5.1.3. Familial Combined Hyperlipidemia
5.1.4. Others
5.2. Global Lipid Disorder Treatment Market by Product Type
5.2.1. Atorvastatin
5.2.2. Simvastatin
5.2.3. Pravastatin
5.2.4. Rosuvastatin
5.2.5. Lovastatin
5.2.6. Other
5.3. Global Lipid Disorder Treatment Market by Distribution Channel
5.3.1. Hospital & Clinics
5.3.2. Retail Pharmacies
5.3.3. Online Pharmacies
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories
7.2. Alnylam Pharmaceuticals, Inc.
7.3. Amarin Corp.
7.4. Astrazeneca Plc
7.5. Avanti Polar Lipids, Inc.
7.6. Cadila Healthcare Ltd.
7.7. Eli Lilly and Co.
7.8. ESPERION Therapeutics, Inc.
7.9. Ionis Pharmaceuticals, Inc.
7.10. Merck & Co. Inc.
7.11. Micelle BioPharma, Inc.
7.12. Moderna, Inc.
7.13. Novartis AG
7.14. Otsuka Pharmaceutical Co., Ltd.
7.15. Pfizer Inc.
7.16. Poxel SA
7.17. Roivant Sciences Ltd.
7.18. Sanofi SA
7.19. Sumitomo Dainippon Pharma Co., Ltd
7.20. Sun Pharmaceutical Industries Ltd.
7.21. Teva Pharmaceutical Industries Ltd.
1. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
2. GLOBAL HYPERCHOLESTEROLEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL DYSBETALIPOPROTEINEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL FAMILIAL COMBINED HYPERLIPIDEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
7. GLOBAL ATORVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
8. GLOBAL SIMVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
10. GLOBAL ROSUVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
11. GLOBAL LOVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
12. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
13. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
14. GLOBAL HOSPITAL & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
15. GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
16. GLOBAL ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
17. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
18. NORTH AMERICA LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
19. NORTH AMERICAN LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
20. NORTH AMERICAN LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
21. NORTH AMERICAN LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
22. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
23. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
24. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
25. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
26. ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
27. ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
28. ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
29. ASIA PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
30. REST OF THE WORLD LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
31. REST OF THE WORLD LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
32. REST OF THE WORLD LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
1. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY INDICATION, 2019 VS 2026 (%)
2. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY PRODUCT TYPE, 2019 VS 2026 (%)
3. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2019 VS 2026 (%)
4. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
5. US LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
6. CANADA LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
7. UK LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
8. FRANCE LIPID DISORDER TREATMENTMARKET SIZE, 2019-2026 ($ MILLION)
9. GERMANY LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
10. ITALY LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
11. SPAIN LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
12. ROE LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
13. INDIA LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
14. CHINA LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
15. JAPAN LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
